Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity

Blood Cancer J. 2024 Feb 6;14(1):26. doi: 10.1038/s41408-024-00988-x.

¹ Flow Cytometry Unit, Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece.
² Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
³ Janssen Research & Development, Spring House, PA, USA.
⁴ Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. ekastritis@med.uoa.gr.

^# Contributed equally.

No abstract available

Publication types